Orexo AB (publ) (STO:ORX)
25.00
+0.30 (1.21%)
At close: Dec 5, 2025
Orexo AB Revenue
Orexo AB had revenue of 118.70M SEK in the quarter ending September 30, 2025, a decrease of -13.04%. This brings the company's revenue in the last twelve months to 543.50M, down -8.76% year-over-year. In the year 2024, Orexo AB had annual revenue of 590.00M, down -7.64%.
Revenue (ttm)
543.50M
Revenue Growth
-8.76%
P/S Ratio
1.58
Revenue / Employee
5.23M
Employees
110
Market Cap
858.20M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 590.00M | -48.80M | -7.64% |
| Dec 31, 2023 | 638.80M | 14.50M | 2.32% |
| Dec 31, 2022 | 624.30M | 59.30M | 10.50% |
| Dec 31, 2021 | 565.00M | -98.60M | -14.86% |
| Dec 31, 2020 | 663.60M | -181.20M | -21.45% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Getinge AB | 35.85B |
| Swedish Orphan Biovitrum AB | 27.85B |
| Medicover AB | 25.67B |
| Elekta AB | 17.57B |
| Asker Healthcare Group AB | 16.41B |
| AddLife AB | 10.53B |
| Nolato AB | 9.57B |
| Vitrolife AB | 3.51B |
Orexo AB News
- 6 weeks ago - Orexo AB (publ) (ORXOY) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Orexo AB (ORXOF) Q3 2025 Earnings Call Highlights: Promising R&D Progress Amidst Market ... - GuruFocus
- 6 weeks ago - Orexo AB (publ) 2025 Q3 - Results - Earnings Call Presentation - Seeking Alpha
- 6 weeks ago - Q3 2025 Orexo AB Earnings Call Transcript - GuruFocus
- 3 months ago - Orexo's AmorphOX technology may pave the way for intranasal GLP-1 medication - PRNewsWire
- 6 months ago - Orexo to present clinical data for OX640 at the EAACI Congress - PRNewsWire
- 8 months ago - Orexo announces positive data for powder-based intranasal vaccine formulated with the AmorphOX technology - PRNewsWire
- 11 months ago - Orexo announces positive topline data from clinical study of OX640 in subjects with and without allergic rhinitis - PRNewsWire